Masakazu Toi
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies 177
- Cancer, Hypoxia, and Metabolism 45
- Oncology top 0.05%
- HER2/EGFR in Cancer Research 149
- Cancer Treatment and Pharmacology 139
- Pulmonary and Respiratory Medicine top 0.1%
- Advanced Breast Cancer Therapies 109
- Genetics top 0.5%
- Estrogen and related hormone effects 65
- Molecular Biology top 0.5%
- Angiogenesis and VEGF in Cancer 70
-
- Breast Lesions and Carcinomas 53
Masakazu Toi
644 papers receiving 21.1k citations
Hit Papers
Peers
Comparison fields: 5 of 164
- Cancer Research 6.9k
- Oncology 10.8k
- Pulmonary and Respiratory Medicine 6.1k
- Genetics 1.7k
- Molecular Biology 8.0k
Countries citing papers authored by Masakazu Toi
This map shows the geographic impact of Masakazu Toi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masakazu Toi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masakazu Toi more than expected).
Fields of papers citing papers by Masakazu Toi
This network shows the impact of papers produced by Masakazu Toi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masakazu Toi. The network helps show where Masakazu Toi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Masakazu Toi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 2 | |
| 5 | 2023 | 4 | |
| 6 | 2023 | 2 | |
| 7 | 2023 | 2 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 4 | |
| 10 | 2023 | 14 | |
| 11 | 2023 | 7 | |
| 12 | Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels | 2022 | 8 |
| 13 | 2022 | 9 | |
| 14 | 2019 | 47 | |
| 15 | 2018 | 77 | |
| 16 | 2018 | 13 | |
| 17 | [Molecular targeted therapy and genomic evolution of breast cancer]. | 2015 | 1 |
| 18 | HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. | 2010 | 12 |
| 19 | Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. | 1999 | 58 |
| 20 | [Significance of tumor angiogenesis as an independent prognostic factor in axillary node-negative breast cancer]. | 1995 | 5 |
About Masakazu Toi
Masakazu Toi is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 666 papers that have together received 21.5k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (177 papers), HER2/EGFR in Cancer Research (149 papers), Cancer Treatment and Pharmacology (139 papers), Advanced Breast Cancer Therapies (109 papers), Angiogenesis and VEGF in Cancer (70 papers), Estrogen and related hormone effects (65 papers), Breast Lesions and Carcinomas (53 papers) and Cancer, Hypoxia, and Metabolism (45 papers). The work is most often cited by research in Cancer Research (6.9k citations), Oncology (10.8k citations), Pulmonary and Respiratory Medicine (6.1k citations), Genetics (1.7k citations) and Molecular Biology (8.0k citations). Masakazu Toi has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Hiroko Bando, Chikashi Nakanishi, Takeshi Tominaga, Takayuki Ueno, Katsumasa Kuroi, Shigehira Saji, Martin Frenzel, Susana Barriga, Norikazu Masuda and Joohyuk Sohn. Their work appears in journals such as Breast Cancer, Journal of Clinical Oncology, Cancer Research, Annals of Oncology and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.